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Abstract
Objectives
To analyze the efficacy and safety of Brivaracetam in pediatric 
patients with epileptic encephalopathy or unresponsive focal 
epilepsy. 
Materials & Methods 
This retrospective study included eight pediatric patients with EE 
or unresponsive focal epilepsy. Inclusion criteria: (1) ≤14 years, (2) 
history of refractory epilepsy, (3) at least one month of continuous 
therapy with BRV, and (4) at least six months of follow-up. Exclusion 
criteria: (1) variation of concomitant antiepileptic drugs during the 
previous and/or subsequent four weeks of the BRV introduction, (2) 
levetiracetam in therapy, (3) epilepsy secondary to the progressive 
cerebral disease, tumor, or any other progressive neurodegenerative 
diseases, and (4) a status epilepticus a month before screening or 
during the baseline period. The efficacy of BRV was defined as 
≥50% of seizure frequency reduction at the end of the follow-up, 
compared to baseline.
Results
All patients showed ≥50% seizure frequency reduction, of whom 
37.5% were seizure-free, 25% had a frequency reduction of ≥75%, 
and 37.5% had frequency reduction of ≥ 50%. All patients with 
an epilepsy onset >12 months and epilepsy duration of ≤6 years 
were seizure-free. The maximum effect was achieved at 2 mg/kg/
day, and focal seizures revealed a better response than epileptic 
encephalopathy. A remarkably positive effect of the Brivaracetam 
was noticed in patients with encephalopathy regarding the status 
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epilepticus during sleep; however, no relevant side-effects 
were noted. 
Conclusion
Brivaracetam was an effective and well-tolerated treatment 
in pediatric patients with epileptic encephalopathy or 
unresponsive focal epilepsy, especially for the epilepsy 
onset >12 months and the epilepsy duration ≤6 years. The 
total effect was not dose-dependent. Brivaracetam could 
represent an indication of encephalopathy regarding the 
status epilepticus during sleep.
Keywords: Brivaracetam; Childhood epilepsy; Drug-
resistant epilepsy; Epileptic encephalopathy
DOI: 10.22037/ijcn.v15i4.29819
Introduction
In the last 20 years, due to the high prevalence of 
therapy-resistant epilepsy, there has been a need 
to develop newer antiepileptic drugs with a more 
recent mechanism of action such as synaptic vesicle 
glycoprotein 2A, a transmembrane glycoprotein, 
and galactose transporter (1- 4).
Brivaracetam is a selective, high-affinity ligand 
for synaptic vesicle glycoprotein 2A, approved 
as adjunctive therapy and monotherapy for the 
treatment of focal seizures in patients aged ≥4 years 
in the United States and for focal seizures with or 
without secondary generalization in patients aged 
≥4 years in the European Union (5, 6). Several 
randomized controlled trials have been conducted 
in the adult population, revealing promising data 
on the efficacy and tolerability of Brivaracetam 
with ≥50% responder rate (7-13).
The results obtained from pre-marketing trials 
were confirmed by subsequent postmarketing 
studies addressing adult patients or a mixed 
population with a small group of pediatric 
subjects with different epileptic conditions, 
including unresponsive focal epilepsy, refractory 
status epilepticus (14-21), generalized epilepsies, 
absence status epilepticus (22), and epileptic 
encephalopathies (23). The literature is limited on 
exclusively pediatric population with unresponsive 
epilepsy, and the existing data come from a phase 
IIA study and a retrospective study (24, 25). In both 
studies, adjunctive treatments with Brivaracetam 
showed a similar responder rate as observed in 
previous studies on adult subjects. However, in the 
phase IIA trial (24), the Brivaracetam therapy was 
administered for only three weeks, and neither was 
the etiology of focal epilepsy specified nor were 
the drug-resistant and non-drug-resistant patients 
separated. In the postmarketing study (25), most 
patients (77%) were currently or previously treated 
with Levetiracetam.
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Given the gap in the literature and the need for 
better documentation of the effectiveness and safety 
of Brivaracetam in children, we conducted this 
retrospective review to analyze the effectiveness 
and tolerability of the adjunctive therapy with 
Brivaracetam in pediatric patients with epileptic 
encephalopathy and unresponsive focal epilepsy.
Materials & Methods
In this study, eight patients with epileptic 
encephalopathy or unresponsive focal epilepsy 
were retrospectively selected from a cohort of 
25 pediatric patients, for whom Brivaracetam 
was used as an add-on therapy. All patients were 
followed up in the IRCCS Neurological Science 
Institute of Bologna and at IRCCS “Medea” La 
Nostra Famiglia of Conegliano from November 
2018 to July 2019.
The clinical diagnosis of epilepsy was supported 
using an electroencephalogram and brain MRI 
imaging. Inclusion criteria were as follows: 1) ≤ 14 
years; 2) history of refractory epilepsy; 3) at least one 
month of continuous therapy with Brivaracetam, 
and 4) at least six months of follow-up. Exclusion 
criteria were (1) variation of concomitant AEDs 
during the previous and/or subsequent four weeks 
of the Brivaracetam introduction, (2) concomitant 
therapy with Levetiracetam, (3) epilepsy secondary 
to progressive the cerebral disease, tumor, or any 
other progressive neurodegenerative disorders, 
and (4) a history of status epilepticus in the month 
before the baseline period or during the follow-up 
phase. 
All patients began Brivaracetam at 1 mg/kg/day. 
According to the clinical response, Brivaracetam was 
increased by 1 mg/kg/day, with a maximum dosage 
of  4 mg/kg/day. Treatment with Brivaracetam was 
discontinued in none of the patients. 
We collected the following clinical data: age at 
epilepsy onset, duration of epilepsy before the 
Brivaracetam, etiology, seizure and epilepsy 
type, and seizure frequency. Seizure types and 
epilepsy syndromes were classified in accordance 
with the International League Against Epilepsy 
classification of epileptic seizures and epileptic 
syndromes (26,27). Seizure frequency was obtained 
from medical notes and seizure diaries. To this end, 
seizure frequencies were averaged and recorded 
monthly for the last three months at baseline and 
the end of the follow-up. Seizure frequency was 
classified as follows: daily (≥ 1 seizure per day) 
and weekly (≥ 4 seizures per month, ≤6 seizures 
per week) seizure; age at epilepsy onset as ≤ 12 
months and > 12 months, seizure frequency as 
≤weekly and daily, and epilepsy duration before 
Brivaracetam as ≤ 6 years and > 6 years. The 
efficacy of Brivaracetam was defined as ≥50% of 
seizure frequency reduction at the end of the follow-
up phase compared to baseline (1 month before 
Brivaracetam), and the patients were considered 
as good responders if the seizure reduction was ≥ 
50% and very good responders if it was ≥ 75%. 
Seizure freedom in the present study was defined 
as complete freedom from all seizures (seizure 
frequency of 0) during the last follow-up phase. 
We considered a dependent variable (namely age 
at epilepsy onset, duration of epilepsy before the 
Brivaracetam, etiology, seizure and epilepsy type, 
and seizure frequency) as “likely influencing” the 
independent variable (seizure frequency) if the 
difference between the two arms of the dependent 
variable was more than 25%.
According to the U.S. Food and Drug Administration 
definitions (28) the appearance of adverse events 
was also checked. Patients or their legal guardians 
submitted written informed consent.
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Results
Of the twenty-five patients initiating Brivaracetam 
therapy, eight met our inclusion/exclusion criteria; 
however, none of the patients withdrew from the 
treatment. 
Table 1 summarizes the participants’ characteristics 
at the baseline and at the end of the follow-up phase. 
The study population included four males and four 
females. The median age of this cohort was 13 
years (ranging from  eight years and four months - 
14 years), and their median age for epilepsy onset 
was seven months (ranging from 1- 96 months). 
Four patients (4/8, 50%) had unresponsive focal 
epilepsy, and four patients (4/8, 50%) had epileptic 
encephalopathy. Among patients with unresponsive 
focal epilepsy, there were two cases of structural 
etiology (focal cortical dysplasia), one case with 
genetic etiology (encephalopathy related to status 
epilepticus during sleep), and one with unknown 
etiology. Of subjects with epileptic encephalopathy, 
three patients had structural etiology (2 Lennox-
Gastaut syndromes and one unknown EE), and one 
patient had genetic etiology (Dravet syndrome).
Intellectual disability was reported in 62.5% of the 
patients (N = 5/8). At the baseline, four patients 
reported the daily frequency of seizures (50% of 
subjects), four subjects the weekly frequency of 
seizures (50% of subjects). The median dose of 
add-on Brivaracetam was 3.5 mg/kg/day (range 
2–4 mg/kg/day). At the end of the follow-up phase, 
all patients (100%) continued the Brivaracetam 
therapy. The mean number of previously-used 
AEDs was 10 (range 3–14), while the mean number 
of concomitant antiepileptic drugs was 2.3 (range 
2–4). 
At a median 8-month follow-up (range 6–11 
months), the overall response rate (≥50% seizure 
frequency reduction) was 100% (8/8 patients). Of 
the participants, three patients were seizure-free 
(37.5%), two cases had a frequency reduction of 
≥ 75% (25%), and three patients had a frequency 
reduction of ≥ 50% (37.5%) (Fig. 1). In all 
patients, the maximum benefit of Brivaracetam 
was achieved at 2 mg/kg/day. No further benefit 
was reported when the daily dose was increased by 
3 mg/kg/day and 4 mg/kg/day. 
As shown in Fig. 2, patients with focal seizures 
tended to respond better (response rate 87.5%) 
than the patients with epileptic encephalopathy 
(response rate 62.5%). 
As shown in Table 2, patients with an epilepsy 
onset > 12 months and duration of epilepsy ≤ 6 
years were seizure-free at the last follow-up 
phase, compared to those with an epilepsy onset 
≤ 12 months and duration of epilepsy > 6 years 
(responder rate of 60%).
No differences was observed between the seizure 
frequency before the Brivaracetam (response rate: 
≤ weekly 81.25%, daily 68.25%) and etiology 
(response rate: genetic etiology 75%, structural 
etiology 81.25%). 
In addition to the seizure-freedom, a 
quick and remarkable improvement of the 
electroencephalogram and behavior was noticed 
in a patient with encephalopathy regarding status 
epilepticus during sleep (Fig. 3). Relevant adverse 
events were reported in none of the patients. 
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Figure 1. Brivaracetam efficacy. VGR: very good responders (≥ 75% seizure reduction); GR: good responders (≥ 50% seizure reduction) 
Figure 2. Brivaracetam responder rate (≥50% seizure reduction) based on type of epilepsy
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Figure 3. Sleep EEG in patient with encephalopathy regarding status epilepticus during sleep. Remarkable improvement could be observed after the 
therapy with Brivaracetam.
Table 1. The participants’ clinic and demographic characteristics
 N=8
Age (years)
Mean ± SD 11.9±2.5




Age at onset of epilepsy (months)
≤ 12 months 5 (62.5%)
> 12 months 3 (37.5%)
Duration of epilepsy (years)
> 6 years 5 (62.5%)
≤ 6 years 3 (37.5%)
Type of epilepsy, N (%)
Focal epilepsy 4 (50%)
Epileptic Encephalopathy 4 (50%)
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Aetiology of epilepsy, N (%)
Structural 5 (62.5%)
Genetic 3 (37.5%)
Frequency of seizures at baseline, N (%)
Daily 4 (50%) 





Mean ± SD 10 ± 3.3
Median (range) 10.5 (3-14)
Table 2. Brivaracetam responder rate (≥50% seizure reduction) based on age at epilepsy onset and duration of epilepsy before Brivar-
acetam treatment.
Number of patients Age at epilepsy onset Duration of epilepsy before 
Brivaracetam
Responder rate
5 ≤ 12 months > 6 years 60%
3 > 12 months ≤ 6 years 100%
Discussion
Although regulatory trials (7-13) and postmarketing 
studies (14-23) have confirmed Brivaracetam as 
an effective and well-tolerated antiepileptic drug, 
the effects of Brivaracetam in pediatric patients 
are less-investigated, especially in the real-world 
clinical settings. 
Only two studies have exclusively addressed the 
pediatric population (24,25). The first was a phase 
IIA, open-label, single-arm, multicenter trial (24), 
and the second one was a retrospective multicenter 
study (25). In these two studies, the efficacy 
and tolerability of the adjunctive treatment with 
Brivaracetam were compared to the previous 
studies on the adult population, with a response 
rate of ≥50%. They reported the most common 
treatment-related adverse events as somnolence 
and decreased appetite; however, the studies had 
some bias.
In the phase II trial, the Brivaracetam was 
administered only for three weeks. Moreover, 
neither was the etiology of focal epilepsy specified, 
nor were the drug-resistant and non-drug-resistant 
patients separated. These limitations imply that 
their main goal was to characterize the steady-state 
plasma concentrations of Brivaracetam oral solution 
and its metabolites and not to address its efficacy 
and tolerability. Most of the patients (77%) were 
currently or previously treated with Levetiracetam 
in the postmarketing study. The authors concluded 
that prior Levetiracetam exposure was reported 
to be associated with lower responder rates, and 
that the tolerability of Levetiracetam might be a 
reason for the high retention (97% at three months) 
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and reasonable responder rates in patients on 
Brivaracetam. 
Our study confirmed the efficacy of previous data 
showing a response rate > 50% (Fig. 1). The best 
response was observed in patients with an epilepsy 
onset > 12 months and duration of epilepsy ≤ 6 
years (100% seizure-free) (Table 2). Moreover, 
better response was achieved in drug-resistant 
focal epilepsies (87.5%) as compared to patients 
with EE (62.5%) (Fig. 2). The most remarkable 
finding was the Brivaracetam response of the 
patient with encephalopathy regarding the status 
epilepticus during sleep, who became seizure-
free with a quick and remarkable improvement in 
the electroencephalogram (Fig. 3) and behavior 
issues. The same finding has not been reported in 
the literature. A better response in unresponsive 
focal epilepsies than for EE was expected due to 
the greater severity of the latter. However, also in 
epileptic encephalopathy, our results were strongly 
positive and in line with the findings of a recent 
adult study on 44 patients with the mean age of 
28.3 ± 14.5 years, suggesting Brivaracetam as 
an effective and well-tolerated antiepileptic drug 
in adult patients with epileptic encephalopathy 
(retention rate of 65% in three months, 52% in six 
months, and 41% in 12 months). 
Another notable result in our study was that the 
overall effect of the Brivaracetam was not dose-
dependent, with a maximum efficacy of 2 mg/kg/
day. In this regard, no similar or comparable data 
have been published yet.  
The main limitation of the present study was 
the retrospective nature of the research, with no 
control group and the inclusion of a small cohort 
of patients with unresponsive epilepsy of various 
etiologies. Another limitation was the relatively 
short follow-up phase, which did not allow the 
long-term outcome expectations.
On the other hand, the advantages of a retrospective 
study was that the findings cannot be predetermined, 
that the evaluations are based on existing data 
sources in which both exposure and outcomes are 
available, and that the findings cannot be tailored 
to the data collected for a specific drug. 
Prospective controlled studies on large 
homogeneous population are required to evaluate 
the long-term effectiveness and tolerability of 
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